AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
These days, it seems like biotech buyout offers are falling from the sky. During the week ended Dec. 6, (NYSE: ABBV) announced not one but two big acquisitions.
The pharma giant's latest big buyout offer is for Cerevel Therapeutics (NASDAQ: CERE), a clinical-stage company developing treatments for schizophrenia and other neurological conditions. Despite not having any approved products to sell yet, AbbVie offered Cerevel $8.7 billion in cash, or $45 per share.
AbbVie's offer came in about 22% above Cerevel's stock price when the market closed on Dec. 6 and 73% more than its closing price on Dec. 1.
Source Fool.com
AbbVie Inc. Aktie
174,06 €
-1,01 %
Einzigartige Zustimmung für AbbVie Inc. mit ausschließlich Buy-Einschätzungen.
Ein positives Kurspotenzial für AbbVie Inc. ist gegeben, mit einem Kursziel von 180 € über dem aktuellen Kurs von 174.06 €.
